By a News Reporter-Staff News Editor at Biotech Week -- A new study on Clinical Trials and Studies is now available. According to news reporting from Paris, France, by NewsRx journalists, research stated, "Atypical hemolytic uremic syndrome (aHUS) is a devastating form of renal thrombotic microangiopathy. Despite plasma exchange, the standard treatment of aHUS for decades, the renal prognosis for patients with aHUS has remained poor."
The news correspondents obtained a quote from the research from the Department of Immunology, "We assessed the off-trial use of eculizumab in adult patients with aHUS affecting the native kidneys. A retrospective study was conducted. aHUS was defined as the presence of 3 or more of the following: acute kidney injury (serum creatinine >1.4 mg/dL [120 mu mol/L]), mechanical hemolytic anemia, thrombocytopenia, and the presence of thrombotic microangiopathy features in a kidney biopsy specimen. Patients who had received 4 or more weekly 900-mg infusions of eculizumab were included. 19 patients were identified through a query sent to all French nephrology centers. Evolution of kidney function, hemolysis, and thrombocytopenia after the initiation of eculizumab therapy. All patients had acute kidney injury (serum creatinine range, 2.2-17.0 mg/dL) and 12 required hemodialysis. Thirteen patients carried a mutation in 1 complement gene and 1 had anti-factor H antibodies. For first-line therapy, 16 patients underwent plasma exchange and 3 patients received eculizumab. Median time between aHUS onset and eculizumab therapy initiation was 6 (range, 1-60) days and median time to platelet count normalization after eculizumab therapy initiation was 6 (range, 2-42) days. At the 3-month follow-up, 4 patients still required dialysis, 8 had non2dialysis-dependent chronic kidney disease, and 7 had normalized kidney function. At last follow-up (range, 4-22 months), 3 patients remained dialysis dependent, 7 had non2dialysis-dependent chronic kidney disease (estimated glomerular filtration rate, 17-55 mL/min/1.73m(2)), and 9 had normal kidney function. Risks of reaching end-stage renal disease within 3 months and 1 year of aHUS onset were reduced by half in eculizumab-treated patients compared with recent historical controls. Limitations: Retrospective study and use of historical controls."
According to the news reporters, the research concluded: "Our data indicate that eculizumab improves kidney disease outcome in patients with aHUS."
For more information on this research see: Insights From the Use in Clinical Practice of Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome Affecting the Native Kidneys: An Analysis of 19 Cases. American Journal of Kidney Diseases, 2014;63(1):40-48. American Journal of Kidney Diseases can be contacted at: W B Saunders Co-Elsevier Inc, 1600 John F Kennedy Boulevard, Ste 1800, Philadelphia, PA 19103-2899, USA. (Elsevier - www.elsevier.com; American Journal of Kidney Diseases - www.elsevier.com/wps/product/cws_home/623276)
Our news journalists report that additional information may be obtained by contacting F. Fakhouri, Hopital Europeen Georges Pompidou, AP HP, Dept. of Immunol, Paris, France. Additional authors for this research include Y. Delmas, F. Provot, C. Barbet, A. Karras, R. Makdassi, C. Courivaud, K. Rifard, A. Servais, C. Allard, V. Besson, M. Cousin, V. Chatelet, J.M. Goujon, J.P. Coindre, G. Laurent, C. Loirat and V. Fremeaux-Bacchi (see also Clinical Trials and Studies).
Keywords for this news article include: Antineoplastic Monoclonal Antibodies, Paris, Drugs, France, Europe, Kidney, Therapy, Eculizumab, Nephrology, Hemolytic Anemia, Thrombocytopenia, Immunologic Agents, Post-Trial Research, Hematologic Diseases, Blood Platelet Disorders, Hemolytic Uremic Syndrome, Clinical Trials and Studies, Hemic and Lymphatic Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC